Literature DB >> 15579767

Prostaglandin E2 mediates phosphorylation and down-regulation of the tuberous sclerosis-2 tumor suppressor (tuberin) in human endometrial adenocarcinoma cells via the Akt signaling pathway.

Kurt J Sales1, Sharon Battersby, Alistair R W Williams, Richard A Anderson, Henry N Jabbour.   

Abstract

Prostaglandin (PG) E2 promotes tumor growth via interaction with its G protein-coupled receptors and activation of intracellular signaling. Tuberous sclerosis 2 (tuberin) is a tumor suppressor, which negatively regulates cell growth. Its phosphorylation results in its inactivation and targeted down- regulation, thus lifting the growth inhibition effects. This study investigated the expression and localization of tuberin in neoplastic and normal endometrium and the effect of PGE2 on phosphorylation of tuberin via the Akt pathway. Quantitative RT-PCR and Western blot analysis demonstrated reduced expression of tuberin in neoplastic tissue, compared with normal endometrial tissue. Tuberin expression was localized by immunohistochemistry to the glandular epithelial compartment in neoplastic and normal endometrium. We investigated the effect of PGE2 on phosphorylation of tuberin via the Akt pathway. Treatment of neoplastic and normal endometrium with 100 nm PGE2 enhanced phosphorylated tuberin immunoreactivity in the glandular epithelium. PGE2 also phosphorylated Akt and tuberin in Ishikawa endometrial adenocarcinoma cells, leading to a reduction in expression of total tuberin protein. Cotreatment of cells with wortmannin or LY294002 inhibited the PGE2-induced phosphorylation of Akt and tuberin. These data suggest that PGE2 signaling may promote endometrial tumorigenesis by inactivation of tuberin after its phosphorylation via the Akt signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579767     DOI: 10.1210/jc.2004-0892

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  cAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4.

Authors:  Sara Blancquaert; Lifu Wang; Sabine Paternot; Katia Coulonval; Jacques E Dumont; Thurl E Harris; Pierre P Roger
Journal:  Mol Endocrinol       Date:  2010-05-19

2.  Hypoxia and prostaglandin E receptor 4 signalling pathways synergise to promote endometrial adenocarcinoma cell proliferation and tumour growth.

Authors:  Rob D Catalano; Martin R Wilson; Sheila C Boddy; Andrew T M McKinlay; Kurt J Sales; Henry N Jabbour
Journal:  PLoS One       Date:  2011-05-12       Impact factor: 3.240

3.  Seminal plasma induces the expression of IL-1α in normal and neoplastic cervical cells via EP2/EGFR/PI3K/AKT pathway.

Authors:  Anthonio O Adefuye; Kurt J Sales; Arieh A Katz
Journal:  J Mol Signal       Date:  2014-08-08

4.  Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer.

Authors:  Jieqi Ke; Yixia Yang; Qi Che; Feizhou Jiang; Huihui Wang; Zheng Chen; Minjiao Zhu; Huan Tong; Huilin Zhang; Xiaofang Yan; Xiaojun Wang; Fangyuan Wang; Yuan Liu; Chenyun Dai; Xiaoping Wan
Journal:  Tumour Biol       Date:  2016-05-26

5.  [Effect of TSC2 gene expression downregulation by lentivirus induced RNA interference on U937 cell line and its mechanism].

Authors:  Z F Xu; H X Liu; Y H Tan; X H Chen; F G Ren; Y F Zhang; J M Chang; N Zhang; J J Hu; H W Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-07-14

6.  F-Prostaglandin receptor regulates endothelial cell function via fibroblast growth factor-2.

Authors:  Margaret C Keightley; Pamela Brown; Henry N Jabbour; Kurt J Sales
Journal:  BMC Cell Biol       Date:  2010-01-21       Impact factor: 4.241

7.  Prostaglandin E2 and F2alpha activate the FP receptor and up-regulate cyclooxygenase-2 expression via the cyclic AMP response element.

Authors:  Kurt J Sales; Vivien Grant; Henry N Jabbour
Journal:  Mol Cell Endocrinol       Date:  2008-02-03       Impact factor: 4.102

8.  Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis.

Authors:  Aadithya Arumugam; Zhiping Weng; Sarang S Talwelkar; Sandeep C Chaudhary; Levy Kopelovich; Craig A Elmets; Farrukh Afaq; Mohammad Athar
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

9.  Aspirin use and endometrial cancer risk: a meta-analysis and systematic review.

Authors:  Yang Wang; Junda Zhao; Xing Chen; Feifei Zhang; Xin Li
Journal:  Ann Transl Med       Date:  2020-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.